Albireo Pharma, Inc. announced the election of Anne Klibanski, M.D., and Stephanie Okey, M.S., to its board of directors. Anne is a proven leader with substantial rare disease research, clinical and hospital system experience, which will be helpful in guiding development efforts. Stephanie's impressive track record of successful commercialization of rare disease therapies will be invaluable, as move to Phase 3 development with A4250 and begin to consider plans for its potential approval and launch.